Appointing an experienced Qualified Person for Pharmacovigilance (QPPV), Local Person for Pharmacovigilance (LPPV), and deputy QPPV/LPPV can require considerable time and resources.
Although the requirements and responsibilities of a QPPV are specified in EU and UK legislation, LPPVs are subject to their own national legislation (e.g., the Graduated Plan Officer "Stufenplanbeauftragter" for Germany), which can also be daunting. As a global pharmacovigilance provider, ProPharma can advise you on the varied requirements for QPPVs and LPPVs to determine the services that will accommodate your business needs and ensure compliance with the pharmacovigilance legislation unique to each location. This will help you to determine your product launch strategy.
Based upon such strategy, ProPharma can provide you with appropriately qualified and experienced QPPVs, LPPVs, and deputies globally. We have a world-wide network of QPPVs and LPPVs to serve you with their expertise from Europe to Australia and in 100 countries.
Every Marketing Authorization Holder (MAH) in Europe has an obligation to establish a pharmacovigilance (PV) system for the fulfillment of PV tasks for its products. When setting up a PV system in Europe, the MAH must appoint an EU QPPV to establish and maintain the MAH’s PV system. In addition to the establishment and oversight of the PV system, the QPPV also has several legislative responsibilities.
Responsibilities of the EU QPPV include:
In addition, many European and other countries legally require a Local Person for Pharmacovigilance (LPPV) at a country level who may report to the EU QPPV (e.g., for Germany a Graduated Plan Officer (GPO) or Stufenplanbeauftragter is required). Although the requirements and responsibilities of an EU QPPV are specified in EU legislation, LPPVs are subject to their own national legislation.
Some QPPVs may have their own network of LPPVs to help fulfill local requirements. As a global pharmacovigilance provider, ProPharma can advise you about the various important requirements for EU QPPVs and LPPVs, to ensure you have the right resources in place to fully comply with the regulations for your PV system in Europe.
Across the European region, the presence and role of an LPPV are dictated by harmonized and country-specific regulations, underscoring a strong focus on pharmacovigilance and patient safety.
Watch or re-watch our "QPPV Office: Ensuring Compliance and Safety in Pharmacovigilance" webinar. This session was packed with valuable information on the roles and responsibilities of the Qualified Person for Pharmacovigilance (QPPV), best practices for maintaining compliance, and strategies for ensuring drug safety.
When submitting marketing authorisation applications (MAAs) in Europe, the applicant (Marketing Authorization Holder, MAH) shall already have set up a pharmacovigilance system. A Summary of the...
Every marketing authorization holder (MAH) needs a pharmacovigilance system to guarantee the safety of its products.
Introduction According to §63a of the German Medicinal Products Act (AMG), a pharmaceutical entrepreneur who places finished medicinal products on the market that are medicinal products within the...
August 28, 2025
Discover how partnering with MI experts at ProPharma can reduce operational burdens, enhance compliance, and improve efficiency for pharmaceutical companies.
August 26, 2025
Successfully expand clinical trials to additional EU Member States under the CTR framework. Explore strategies for patient recruitment, regulatory compliance, and minimizing CTIS approval delays.
August 25, 2025
Discover the essentials of selecting the right pharmacovigilance vendor for post-marketing safety, ensuring compliance, flexibility, and effective signal detection.
July 8, 2025
ProPharma appoints former FDA labeling expert as VP, Labeling & Strategy, enhancing strategic labeling, promotional review, and regulatory consulting expertise to accelerate drug development and...
January 31, 2025
ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.
October 21, 2024
ProPharma appoints Brian Tuttle as CFO to drive financial strategy and accelerate global growth, leveraging his 20 years of life sciences industry experience.
.png?width=320&height=185&name=Global%20MLR%20Review%20(RS).png)
